Endocrine Society CMES Ancillary Symposia
These ancillary symposia were developed through The Endocrine Society’s Continuing Medical Education Services (CMES). They will be held at the San Francisco Marriott Hotel either before or after the ENDO 08 plenary sessions (unless otherwise indicated).
As an accredited provider of continuing medical education (CME), it is The Endocrine Society's policy to ensure that the contents and quality of these educational activities are balanced, independent, objective, and scientifically rigorous. The scientific content of these activities was developed under the supervision of the Special Programs Committee of The Endocrine Society. The commercial supporters of these activities have no influence over the selection of the faculty or specific presentations.
All ancillary symposia are CME accredited by the Society, and planned and conducted in strict compliance with the Essential Standards & Guidelines of the Accreditation Council for Continuing Medical Education. Symposia are subject to change.
CMES Ancillary Symposia are held at the San Francisco Marriot (unless otherwise indicated). There is no cost to attend. However, seating is limited; therefore Reservation Tickets are made available via the ENDO 08 Registration System. Reservation Tickets are valid for 15 minutes after the advertised opening time listed below. After 15 minutes, seating will be made available to all attendees on a first-come, first-served basis.
Using Continuous Glucose Monitors to Improve Diabetes Care: A Review of the Latest Research and Clinical Practice Strategies
A CMES Workshop Co-sponsored by The Endocrine Society & The Juvenile Diabetes Research FoundationDate/Time: Saturday June 14, 2:30 pm -5:30 pm, Moscone Center, Room 132
Program Directors: Jennifer Larsen, MD - Univ of Nebraska & Aaron Kowalski, PhD - JDRF
CME credits: 2.5 hours
Overview of Devices: Methodology and Limitations - Speaker TBD
Algorithms/Tools to Optimize CGM Utilization – Jen Block, RN, CDE Stanford Univ Medical Center
Clinical Use of Continuous Glucose Monitoring – Panel Case Presentations – Irl B. Hirsch, Univ of Wash Medical Center, Bruce Buckingham, MD, Stanfor Univ School of Med, Lois Jovanovich, MD, Sansum Diabetes Research Institute
Upon completion of this educational activity, participants should be able to: 1) Understand the indications and limitations of continuous glucose monitors available at the present time; 2) Contrast the features of existing continuous glucose monitoring devices available; and 3) utilize continuous glucose monitoring data to make clinical decisions.
Neurocognitive and Novel Therapeutic Aspects of Hyponatremia
Supported by an educational grant from Otsuka America Pharmaceutical, Inc.Date/Time: Sunday, 6/15, 6:00 am -8:00 am, San Francisco Marriott; Yerba Buena Ballroom Salon 8
Program Director: Joseph G. Verbalis, MD - Georgetown University
CME credits: 1.5 hours
Neurological and Cognitive Manifestations of Acute and Chronic Hyponatremia – Richard H. Sterns, MD – Rochester General Hospital
Clinical Trials of Vasopressin Receptor Antagonists to Treat Hyponatremia – Joseph G. Verbalis, MD – Georgetown Univ
Evaluation and Management of Hyponatremia in Brain Injured Patients: Differentiating SIADH from Cerebral Salt Wasting – Stephan A. Mayer, MD – Columbia University
Upon completion of this educational activity, participants should be able to: 1) Recognize the full spectrum of neurological complications of hyponatremia, from hyponatremic encephalopathy with acute hyponatremia to the more subtle neurocognitive deficits associated with chronic hyponatremia.
2) Review the evidence demonstrating gait instability and an increased risk of falls in hyponatremic patients, with particularly important potential consequences for elderly patients. 3) Describe current and emerging treatments of hyponatremia, with especial emphasis on the clinical trial data that support use of vasopressin receptor antagonists (vaptans) to treat hyponatremia, including the limitations and potential side effects of vaptans. 4) Understand current accepted treatment indications, and contraindications, for using vaptans in hyponatremic patients. 5) Review the differential diagnosis of hyponatremia based on the ECF volume status both in hospital and ambulatory settings. 6) Appreciate the criteria for diagnosing of SIADH versus cerebral salt wasting in patients with brain injury, and how this impinges on the decision of whether to use vaptans as therapy in such patients.
Recent Advances in Mild Thyroid Failure
Supported by an educational grant from Abbott LaboratoriesDate/Time: Sunday, 6/15, 6:00 am – 8:00 am, San Francisco Marriott; Yerba Buena Ballroom Salon 7
Program Director: David S. Cooper, MD - Sinai Hospital of Baltimore
CME Credits: 1.5 hours
Mild Thyroid Failure and the Heart. - Anne Cappola,MD - Univ of Penn Sch of Med
The Impact of Mild Thyroid Failure on Mood and Cognition - Mary Samuels, MD – Oregon Health Sci Univ
Pregnancy and Mild Thyroid Failure - Alex Stagnaro-Green, MD – Touro Univ Coll of Med
The overall educational goals for this continuing medical education program are to: 1) Summarize the latest data on cardiovascular outcomes in mild thyroid failure; 2) Provide a framework for evaluating observational studies of mild thyroid failure; 3) Summarize the latest data on cognitive function and mood alterations in mid thyroid failure; 4) Utilize recent data on cognitive function and mood to make rational treatment decisions in patients with mild thyroid failure; 5) Discuss the impact of mild thyroid failure on miscarriage, preterm delivery and IQ in the unborn child; and 6) Discuss the pros and cons of screening strategies for thyroid disease during pregnancy.
Unraveling the Complexities of Menopause Management: CME Experience
Supported by an educational grant from Wyeth PharmaceuticalsDate/Time: Sunday, 6/15, 6:15 pm – 10:00 pm, San Francisco Marriott; Yerba Buena Ballroom, Salon 9
Program Directors: Richard J. Santen, MD - University of Virginia Health System & Nanette F. Santoro, MD - Albert Einstein College of Medicine
CME credits: 3.25 hours
Professional Exchange
Critical Issue of Disentangling Menopause From Aging - Nanette F. Santoro, MD – Albert Einstein College of Medicine & S. Mitchell Harman, MD, PhD – Kronos Longevity Research Institute
Applying an Understanding of the Mechanisms of Action of Estrogen and SERMs to Patient and Treatment Selection in Clinical Practice - Donald P. McDonnell, PhD – Duke University Medical Center
Putting the WHI Study into Clinical Perspective - Cynthia A. Stuenkel, MD – University of California-San Diego
Are All SERMs the Same? - William H. Catherino, MD, PhD – Uniformed Services University & Regine Sitruk-Ware, MD –The Population Council, Center for Biomedical Research
Lecture Series
Selecting Candidates for Fracture Prevention Based on Risk Prediction - Lubna Pal, MD – Yale University School of Medicine
Efficacy and Safety Profiles of New and Emerging Menopause Treatments - Kathryn A. Martin, MD – Harvard University/Massachusetts General Hospital
Future Treatment Strategies for Menopausal Symptom Management - Richard J. Santen, MD – University of Virginia Health System
Starting and Stopping Hormone Therapy - Marcelle I. Cedars, MD –University of California-San Francisco
Upon completion of this educational activity, participants will be able to: 1) Assess the potential role of ET, HT, and SERMs in treatment regimens in menopausal women utilizing an understanding of estrogen receptors, estrogen signaling pathways, and selectivity; 2)Assess the mechanisms of action, efficacy, safety, and clinical/patient considerations of ET, HT, and SERM therapies to develop customized therapeutic interventions for menopausal women that improve their outcomes; 3) Evaluate the potential burden of disease resulting from menopause; 4) Assess the pros and cons of ET and HT therapy based on the most recent insights into the WHI study analyses and patient selection criteria for these agents to integrate these agents into successful therapeutic regimens for optimal outcomes in menopausal patients; 5) Differentiate the selectivity, potency, and mechanisms of action of current and emerging SERMs to identify the optimal SERM profile for customized therapy for menopausal patients; and 6)
Utilize an understanding of ET, HT, and SERM therapy-related side effects, develop interventions that minimize side effects in order to maintain patients on therapy with optimal QOL.
The Clinical Science of Incretins: Examining the Beta Cell and the Complex Nature of Type 2 Diabetes
Supported by an educational grant from Novo Nordisk Inc.Date/Time: Sunday, 6/15, 6:30 pm 9:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 7
Program Director: David A. D’Alessio, MD - Univ of Cincinnati
CME credits: 2.5 hours
Uncovering Clues in the Investigation of Type 2 Diabetes: The Role of β-Cell Dysfunction - Jack Leahy, MD – Univ of Vermont Coll of Med
Under the Microscope: Examining the Direct and Indirect Effects of GLP-1 - Ananda Basu, MD, MRCP - Mayo Clinic
Making the Case: Direct and Indirect Benefits of Incretin-Based Therapies - Richard E. Pratley, MD – Univ of Vermont
Upon completion of this educational activity, participants will be able to: 1) Describe the multiple metabolic defects that occur in type 2 diabetes; 2) List the 2 primary incretin hormones, and explain the incretin effect; 3) Describe defects in incretin secretion and incretin action that occur in type 2 diabetes; 4) Summarize the direct and indirect effects of native GLP-1 on metabolism and on β-cell mass and function; 5) Discuss the clinical efficacy and safety of incretin-based therapies for the treatment of type 2 diabetes; and 6) Discuss the appropriate clinical application of incretin-based therapies, including proper patient selection based on clinical need and current glycemic control.
Pathways in the Control of Metabolism: Emerging Links
Sponsored by The Endocrine Society’s Corporate Liaison BoardDate/Time: Sunday, 6/15, 6:30 pm – 9:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 8
Program Director: Sethu Reddy, MD, MBA, FRCPC, FACP, MACE – Merck & Co.
CME credits: 2.5 hours
Pediatric Obesity Syndromes: Beyond Leptin and the Melanocortin 4 Receptor - Jack Yanovski, MD, PhD - NICHD/NIH
Integrated Neurohormonal Control of Body Weight: Implications for Obesity Drug Development - Christian Weyer, MD, MAS – Amylin Pharmaceuticals
Bone Regulation of Glucose Metabolism - Gerard Karsenty, MD, PhD - Columbia University Medical Center
Upon completion of this educational activity, participants will be able to: 1) Be aware of some emerging links between long-term adiposity and short-term satiety signals in the neurohormonal regulation of energy homeostasis; 2) Recognize the importance of studying the interaction of weight-regulating neurohormones, as exemplified by the weight loss synergy observed with leptin and amylin agonism in diet-induced obesity; 3) Describe how scientific advances in neurohormonal regulation of body weight may translate into novel, innovative approaches to obesity drug development; 4) Describe pediatric obesity syndromes caused by dysfunction of genes in the leptin signaling pathway; 5) Understand the importance of the interactions between melanocortin receptors, developmental genes including SIM1, and downstream effector systems including brain-derived neurotrophic factor, for body weight regulation; 6) Demonstrate the existence of a link between bone and energy metabolism; 7) Present one clinically relevant example of the importance of this cross-talk; 8) Recognize how a genetic approach to physiology can open new avenues for the treatment of metabolic diseases.
Current Challenges and Future Opportunities in the Treatment of Testosterone Deficiency in Men
Supported by an educational grant from Solvay Pharmaceuticals, Inc.Date/Time: Monday, 6/16, 6:00 am – 8:00 am, San Francisco Marriott; Yerba Buena Ballroom Salon 7
Program Director: Shalender Bhasin, MD – Boston University
CME Credits: 1.5 hours
Relationship of Testosterone to Metabolic Syndrome and Cardiovascular Risk – Shehzad Basaria, MD – John Hopkins Univ
Effect of Hypogonadism on Cognitive Function – Alvin Matsumoto, MD – VA Puget Sound Health Care System, Seattle
SARMs: Will Their Promise be Realized? - Shalender Bhasin, MD – Boston University
Upon completion of this educational activity, participants will be able to: : 1) Evaluate the data on testosterone deficiency and cardiovascular mortality; 2) Review the mechanisms of action of selective androgen receptor modulators under investigation; and 3) Review the proposed benefit of testosterone on cognitive function.
Medullary Thyroid Cancer
Supported by an educational grant from AstraZenecaDate/Time: Monday, 6/16, 6:00 am – 8:00 am, San Francisco Marriott; Yerba Buena Ballroom Salon 8
Program Director: R. Michael Tuttle, MD – Memorial Sloan-Kettering Cancer Center
CME Credits: 1.5 hours
Clinical Challenges for Conventional Treatment of Medullary Thyroid Carcinoma – Richard T. Kloos, MD - Ohio State University
Molecular Pathways and Targets for Therapy of Medullary Thyroid Cancer - Robert F. Gagel, MD - University of Texas- MD Anderson Cancer Center
Clinical Trials Using Targeted Therapies for Medullary Thyroid Cancer – Samuel A. Wells, Jr, MD - Washington University School of Medicine
Upon completion of this educational activity, participants will be able to: 1) Select the most appropriate treatment strategies to manage medullary thyroid cancer; 2) Recognize presenting tumor features that presage aggressive medullary thyroid cancer; and 3) Discuss current knowledge of the molecular genetics of medullary thyroid cancer and emerging evidence of the usefulness of investigational compounds that may be used to halt MTC progression.
Management of Pituitary Adenomas
Supported by an educational grant from Novartis Pharmaceuticals CorporationDate/Time: Monday, 6/16, 6:00 am – 8:00 am, San Francisco Marriott; Room: Yerba Buena Ballroom Salon 9
Program Director: Beverly M.K. Biller, MD – Harvard Medical School
CME credits: 1.5 hours
Merits of Pharmacologic vs. Surgical Therapy for Acromegaly – Prof. Stephan M. Shalet, BSc, MD, FRCP – Christie Hospital, UK
Pharmacologic Treatment of Prolactinomas: When is it Appropriate to Discontinue? – Janet A. Schlechte, MS, MD – University of Iowa
Pharmacologic Therapy for Cushing's: The Old and the New – Lynnette K. Nieman, MD – National Institutes of Health - NICHD
Upon completion of this educational activity, participants will be able to: 1) Explain the risks and benefits of surgical, medical, and radiotherapeutic treatment options for pituitary adenomas; 2) Choose and implement the most appropriate therapeutic modalities for the treatment of ACTH-producing pituitary adenomas; 3) Select the most appropriate therapeutic modalities for the treatment of acromegaly; and 4)Assess individual patient profiles in choosing to continue or withdraw medical therapy for prolactinoma.
Incretins: Evolving Science and Emerging Strategies
Supported by an educational grant from Merck & Co., Inc.Date/Time: Monday, 6/16, 6:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 8
Program Director: Guillermo Umpierrez, MD – Emory University
CME credits: 2.5 hours
Current And Future Use of Incretins
Incretins and b-Cell Preservation
Non-glucose Effects of Incretins
Upon completion of this educational activity, participants will be able to: 1) Describe the benefits of early detection and management of diabetes and the emerging role of incretin-based therapies for slowing disease progression and optimizing glycemic control; 2) Examine evidence for beta cell preservation with the use of incretins and discuss potential future applications of incretins for diabetic patients; and 3) Evaluate the effects of incretins beyond regulation of glucose homeostasis
Are We Providing State-of-the-Art Care for Girls and Women with Turner Syndrome?
Supported by an educational grant from Novo Nordisk Inc.Date/Time: Monday, 6/16, 6:30 pm – 9:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 7
Program Director: Carolyn Bondy, MS, MD – National Institutes of Health, NICHD
CME credits: 2.5 hours
Critical New Issues in the Care of Girls and Women with Turner Syndrome - Carolyn Bondy, MS, MD, National Institutes of Health
Optimizing Growth and Age-Appropriate Puberty - Marsha Davenport, MD – Univ of North Carolina, Chapel Hill
Estrogen, Growth, and Cognition - Judith Ross, MD - Jefferson Med College
Have We Dropped the Ball with the Adult Patient? - Claus Hojbjerg Gravholt, MD - Aarhus University Hospital – Denmark
Upon completion of this educational activity, participants will be able to: 1) Explain the benefits of earlier recognition of Turner syndrome and the importance of referral for multiple specialty needs; 2) Describe the benefits of early hormone therapy for growth as well as puberty; 3) Review the issue of neurocognitive impairment in patients with Turner syndrome; and 4) Discuss the needs of adult Turner syndrome patients as they transition from pediatric to adult care.
Case-based Management Discussions in Acromegaly and New Options in Medical Therapy
Supported by an educational grant from Tercica, Inc.Date/Time: Monday, 6/16, 6:30 pm – 9:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 9
Program Director: Anne Klibanski, MD, Massachusetts General Hospital
CME credits: 2.5 hours
Surgical Fairlure – What Are the Options? – Lisa Nachtigall, M - Mass General Hosp
Assessment of Needs for Combination Therapy – Aart Jan Van Der Lely, MD, PhD – Erasmus Medical Center
Heart Disease and Acromegaly – Annamarie Colao, MD, PhD – Univ Frederico I of Naples
Upon completion of this educational activity, participants will be able to: 1) Determine whether surgery, radiation, or medication therapy is the most appropriate treatment based on the clinical scenario of a patient with acromegaly; 2) Discuss new data relating combination therapies in treating patients with acromegaly; and 3) Discuss the outcomes, such as cardiac valve disease, associated with the use of dopamine agonists in managing patients with pituitary tumors.
Integration of Dyslipidemia Treatment and Glycemic Control to Manage Cardiovascular Risk in Type II Diabetes
Supported by an educational grant from Daiichi Sankyo, Inc.Date/Time: Tuesday, 6/17, 6:00 am – 8:00 am, San Francisco Marriott; Yerba Buena Ballroom Salon 7
Program Director: Alan Chait, MBBS, MS, MD - Univ of Washington
CME credits: 1.5 hours
Epidemiology and Burden of CVD in Patients with T2DM – Om Ganda, MD – Harvard Medical School
Strategies for Treatment of Dyslipidemia in Patients with T2DM and the Effect on CVD Risk – Robert Ratner, MD – MedStar Research Institute
Strategies for Glycemic Control in T2DM and How They Might Affect CVD Risk – Franklin Zieve, MD, PhD – McGuire, VA Medical Center
Integrating Dyslipidemia Treatment and Glycemic Control in Patients with T2DM – Peter Gaede, MD, Steno Diabetes Center, Denmark
Upon completion of this educational activity, participants will be able to: 1) Describe characteristics that place patients with diabetes at disproportionally high risk for cardiovascular disease; 2) Apply aggressive lipid-lowering strategies to achieve recommended goals in patients with type 2 diabetes (T2DM) and dyslipidemia; 3) Integrate clinical trial data to best manage dyslipidemia and achieve glycemic control in patients with T2DM; and 4) Explain treatment strategies and the role for combination therapies in patients with type 2 diabetes
Controversies in Managing IGFD and the Role of Combination GH/IGF-I for Children and Adults
Supported by an educational grant from Tercica, Inc.Date/Time: Tuesday, 6/17, 6:30 pm – 9:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 7
Program Director: Ron Rosenfeld, MD - Lucile Packard Foundation for Children’s Health
CME credits: 2.5 hours
Diagnostic Tests for Primary and Secondary IGFD – Martin Savage, MD – Barts & The London School of Medicine & Dentistry
Defining GH Responsiveness and Unresponsiveness – Peter Clayton, MD – Royal Manchester Children’s Hospital
The Rationale for Combination Therapy – Andrew Hoffman, MD – Stanford University
Upon completion of this educational activity, participants will be able to 1) Evaluate the diagnostic tests and molecular factors that differentiate primary and secondary IGFD; 2) Differentially diagnose primary and secondary IGFD; 3) Identify patients who are not responding to GH or IGF-I therapy; and 4) Select appropriate therapeutic options for unresponsive patients; and 5) Determine if there is a theoretical basis for combination therapy with GH/IGF-I in children and adults.
New Targets and Changing Paradigms in the Treatment of Obesity to Reduce Cardiovascular and Metabolic Risk
Supported by an educational grant from sanofi aventis U.S. Inc.Date/Time: Tuesday, 6/17, 6:30 pm – 9:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 8
Program Director: TBD
CME credits: 2.5
Adipose Tissue's Role in Promoting Cardiometabolic Risk – Kevin D. Niswender, MD, PhD – Vanderbilt University Medical Center
Promoting Effective Lifestyle Intervention for Managing Obesity and Comorbidities – Daniel H. Bessesen, MD – University of Colorado at Denver
Tailoring Pharmacotherapy for Obesity and Comorbidities – hoursHolly R. Wyatt, MD – University of Colorado at Denver
Upon completion of this educational activity, participants will be able to: 1) Describe the epidemiology of obesity and metabolic syndrome, their costs to society and the role of excess adipose tissue in elevating cardiovascular risk; 2) Describe the endocannabinoid system and explain its role in the central endocrine regulation of energy homeostasis; 3) Critically evaluate novel therapeutics that target the endocannabinoid and endocrine systems; and 4) Determine cardiovascular event risk and implement appropriate behavioral and medical treatment options for its reduction.
Low Testosterone: Diagnosis, Monitoring, and Benefit
Supported by an educational grant from Auxilium PharmaceuticalsDate/Time: Tuesday, 6/17, 6:30 pm – 9:30 pm, San Francisco Marriott; Yerba Buena Ballroom Salon 9
Program Director: Adrian Dobs, MHS, MD - Johns Hopkins Univ School of Med
CME credit: 2.5 hours
Diagnostic Dilemmas in the Diagnosis of Male Hypogonadism - Speaker - Ronal Swerdloff, MD – UCLA Medical Center
Issues in Monitoring Testosterone Treatment – Glenn Cunningham, MD – Baylor College of Medicine
Effects of Replacement Therapy on Bone – Joel Finkelstein, MD – Mass General Hospital
Upon completion of this educational activity, participants will be able to: 1) Assess the diagnostic criteria for hypogonadism, particularly in regard to utilization of assays, and specific patient populations such as aging males and illness; 2) Describe issues with regard to monitoring, both for efficacy and safety; and 3) Understand the effects of replacement therapy on bone.